Maud Toulmonde Selected Research

Maud Toulmonde Research Topics

Disease

25	Sarcoma (Soft Tissue Sarcoma) 01/2024 - 05/2010
22	Neoplasms (Cancer) 01/2024 - 01/2016
6	Disease Progression 01/2023 - 01/2016
6	Neutropenia 01/2022 - 04/2015
4	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2017
4	Fatigue 01/2022 - 04/2015
4	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 08/2019 - 05/2012
3	Tertiary Lymphoid Structures 01/2024 - 01/2021
3	Ewing Sarcoma (Sarcoma, Ewing) 01/2023 - 10/2017
3	Nausea 01/2022 - 01/2017
3	Hypertension (High Blood Pressure) 01/2019 - 01/2016
3	Leiomyosarcoma 04/2017 - 04/2015
3	Thrombocytopenia (Thrombopenia) 01/2017 - 04/2015
2	Brain Diseases (Brain Disorder) 06/2023 - 01/2016
2	Hemangiosarcoma (Angiosarcoma) 05/2023 - 01/2022
2	Aggressive Fibromatosis (Desmoid) 01/2021 - 01/2019
2	Vomiting 01/2021 - 01/2017
2	Osteosarcoma (Osteogenic Sarcoma) 01/2020 - 10/2017
2	Pruritus (Itching) 01/2018 - 08/2015
2	Pigmented Villonodular Synovitis 01/2018 - 08/2015
2	Liposarcoma 10/2017 - 12/2016
2	Febrile Neutropenia 01/2017 - 04/2015
2	Asthenia 12/2016 - 08/2015
1	Amyloidosis 01/2023
1	Breast Neoplasms (Breast Cancer) 12/2022
1	Carcinoma (Carcinomatosis) 01/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022
1	Alopecia (Baldness) 01/2021
1	Pain (Aches) 01/2021
1	Sarcopenia 12/2020
1	Pneumothorax 01/2020
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019
1	Dizziness (Lightheadedness) 01/2018
1	Headache (Headaches) 01/2018
1	Anorexia 01/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018

Drug/Important Bio-Agent (IBA)

7	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 11/2010
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2024 - 10/2022
5	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2020
5	Ifosfamide FDA LinkGeneric 06/2023 - 11/2010
4	Sunitinib (Sutent)FDA Link 08/2019 - 05/2012
4	Imatinib Mesylate (Gleevec)FDA Link 08/2019 - 05/2012
3	TrabectedinIBA 01/2024 - 04/2015
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2018
3	AnthracyclinesIBA 01/2021 - 12/2016
3	Biomarkers (Surrogate Marker)IBA 08/2019 - 01/2018
2	avelumabIBA 01/2024 - 01/2022
2	Trinitrotoluene (TNT)IBA 08/2023 - 04/2017
2	pembrolizumabIBA 10/2022 - 01/2020
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 01/2020
2	regorafenibIBA 01/2022 - 12/2016
2	AntibodiesIBA 01/2021 - 01/2018
2	palbociclibIBA 08/2019 - 01/2019
2	pazopanib FDA Link 01/2019 - 01/2016
2	Macrophage Colony-Stimulating FactorIBA 01/2018 - 08/2015
2	Alanine Transaminase (SGPT)IBA 01/2017 - 04/2015
1	Sorafenib (BAY 43-9006)FDA Link 06/2023
1	AntiemeticsIBA 06/2023
1	Aprepitant (Emend)FDA Link 06/2023
1	Vincristine (Oncovin)FDA LinkGeneric 01/2023
1	Etoposide (VP 16)FDA LinkGeneric 01/2023
1	Circulating Tumor DNAIBA 01/2023
1	Insulin (Novolin)FDA Link 01/2023
1	Toll-Like Receptor 4IBA 10/2022
1	PlatinumIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Alanine (L-Alanine)FDA Link 01/2022
1	durvalumabIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	nintedanibIBA 01/2021
1	erdafitinibIBA 12/2020
1	cyclopropapyrroloindoleIBA 12/2020
1	EnzymesIBA 01/2020
1	atezolizumabIBA 01/2020
1	KynurenineIBA 01/2020
1	CytokinesIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	cabozantinibIBA 01/2020
1	Tryptophan (L-Tryptophan)FDA Link 01/2020
1	navoximodIBA 01/2020
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2020
1	Vinyl Chloride (Chloroethylene)IBA 01/2019
1	Methotrexate (Mexate)FDA LinkGeneric 01/2019
1	DioxinsIBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2019
1	ChlorophenolsIBA 01/2019
1	tazemetostatIBA 01/2018
1	Lapatinib (GW572016)FDA Link 01/2018
1	Dasatinib (BMS 354825)FDA Link 01/2018
1	Trastuzumab (Herceptin)FDA Link 01/2018

Therapy/Procedure

12	Drug Therapy (Chemotherapy) 05/2023 - 05/2010
9	Therapeutics 01/2024 - 01/2017
3	Immunotherapy 01/2020 - 01/2018
2	Adjuvant Chemotherapy 01/2022 - 01/2018
2	Radiotherapy 02/2021 - 01/2018
2	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 04/2017
1	Aftercare (After-Treatment) 10/2022
1	Cryosurgery 01/2021
1	Neoadjuvant Therapy 01/2021